Novartis AG (Novartis AG) Change In Payables And Accrued Expense : $98 Mil (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Change In Payables And Accrued Expense?

Novartis AG's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-409 Mil. It means Novartis AG's Accounts Payable & Accrued Expense declined by $409 Mil from Dec. 2023 to Mar. 2024 .

Novartis AG's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $479 Mil. It means Novartis AG's Accounts Payable & Accrued Expense increased by $479 Mil from Dec. 2022 to Dec. 2023 .

Novartis AG Change In Payables And Accrued Expense Historical Data

The historical data trend for Novartis AG's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Change In Payables And Accrued Expense Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

553.00

-324.00

-111.00

-181.00

479.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															26.00	127.00	-184.00	564.00	-409.00

Novartis AG Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $98 Mil.

Novartis AG Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Novartis AG's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.